PharmaEssentia (藥華藥) announced on the 5th a consolidated revenue of NT$1.92 billion for December 2025, representing a 69.93% YoY increase. This milestone set new historical highs for monthly, quarterly, and annual revenue. The company attributed this surge to the 65% and 45% expansion of its US and Japanese sales teams, respectively.

Operational Highlights:

• J.P. Morgan Healthcare Conference: The company has been invited to present at the 44th JPM Conference on January 15 in San Francisco to brief international investors on its progress.
• Pipeline Milestone: The US FDA has begun substantive review of Ropeg (Besremi) for Essential Thrombocythemia (ET). PharmaEssentia responded to FDA Information Requests (IRs) regarding statistics and clinical data on January 5. If successful, US approval for ET is expected in 1H 2026.
• Medicare Part D Relief: Following a US court ruling, the CMS has allowed the company to suspend certain drug discount payments while reassessing its "Specified Small Manufacturer" status. If granted, this will allow for a phased implementation of the Medicare Part D manufacturer discount program.

Resource: 藥華藥12月營收19.2億元 單月、單季、全年三創新高